GlaxoSmithKline CEO would consider dividing following the Novartis deal
Should GlaxoSmithKline split up into various smaller companies? Investor Neil Woodford thinks so.
Despite bribery scandal, GSK ready to expand in China
Despite its recent, ugly bribery scandal, CEO Andrew Witty says that GlaxoSmithKline has a strong expansion plan in China.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
GSK joins neglected disease pact as pharmas eye emerging markets
Neglected tropicals diseases affect more than one billion people globally, but they have not figured prominently in pharmaceutical industry plans. Those priorities look to be changing with today’s announcement that 13 pharma companies, including GlaxoSmithKline (NYSE:GSK), are joining with public sector and nonprofit partners to control or eliminate neglected tropical diseases (NTDs). The partnership includes […]
GSK’s Andrew Witty knighted over the New Year
That’s Sir Andrew Witty to you. The CEO of GlaxoSmithKline (NYSE:GSK) was knighted on Dec. 31 for “services to the economy and to the UK pharmaceutical industry.” The honor, among other things, comes with the title of “Sir.” This year’s list isn’t without its controversial figures — it included a dodgy hedge-fund tycoon and political […]
GSK’s Witty pumps up the pharma’s drug pipeline prospects
GlaxoSmithKline (NYSE:GSK) CEO Andrew Witty has been trying to plant seeds of optimism in an investor community that sees little reason for optimism in the global financial markets. The Independent, a London newspaper, reports that Witty told investors at a recent dinner that drug pipeline of the Britain-based pharma giant “will transform the company.” At […]